Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) has announced a registered direct offering of 22,277,750 common shares and pre-funded common share purchase warrants at a price of US$6.51 per share or pre-funded warrant, resulting in aggregate gross proceeds of approximately US$175 million. The offering includes participation from new and existing institutional investors such as Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, Acorn Bioventures, Spruce Street Capital, Squadron Capital Management, Adage Capital Partners LP, Boxer Capital Management, ADAR1 Capital Management, Stonepine Capital Management, Pivotal Bioventure Partners, and Ally Bridge Group.
Each share or pre-funded warrant is accompanied by 0.35 of one common share purchase warrant exercisable at US$8.14 per share. The warrants will expire on the earlier of June 30, 2027, 30 days after topline data is released for the APPROACH trial of CYB003 in major depressive disorder, or 30 days after an acceleration notice if the NYSE American closing price equals or exceeds US$19.53 for five consecutive trading days. This structure provides investors with potential upside while aligning with key clinical milestones.
Cybin is a late-stage breakthrough neuropsychiatry company focused on developing next-generation treatments for mental health conditions. The company's lead program, CYB003, is a proprietary deuterated psilocin analog currently in Phase 3 studies for the adjunctive treatment of major depressive disorder. CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to address a significant unmet need. Additionally, Cybin is developing CYB004, a deuterated N,N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder.
The substantial capital raise underscores investor confidence in Cybin's pipeline and the growing interest in psychedelic-based therapies. The funds are expected to support the continued development of CYB003 and CYB004, including the pivotal APPROACH trial for major depressive disorder. Major depressive disorder affects millions worldwide, and current treatments often have limited efficacy or significant side effects. Cybin's approach aims to provide rapid and durable symptom relief with a favorable safety profile.
The offering also strengthens Cybin's financial position, enabling it to advance its research pipeline of investigational 5-HT-receptor focused compounds. The company operates in Canada, the United States, the United Kingdom, and Ireland, with a mission to revolutionize mental healthcare. For more details on the offering, visit the full press release here.
This funding event is a critical milestone for Cybin as it moves toward potential regulatory submissions and commercialization. The participation of top-tier healthcare and investment firms signals strong institutional support for the company's vision and scientific approach. As mental health challenges continue to rise, innovative therapies like those being developed by Cybin could offer new hope for patients.
